Navigation Links
NeoStem, Inc. Awarded NIH Research and Research Infrastructure 'Grand Opportunities' Grant
Date:10/6/2009

NEW YORK, Oct 6 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holder of the exclusive, worldwide license to VSEL(TM) Technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that it has been awarded a grant of $108,746 for the repair of bone defects by human stem cells under the American Recovery and Reinvestment Act (RRA) of 2009 from the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of the National Institutes of Health (NIH).

This award will fund studies to investigate the potential of very small embryonic-like stem cells to regenerate bone in an animal model. These very small embryonic-like stem cells are isolated from adults' own peripheral blood using NeoStem's proprietary isolation methods. The Company intends to undertake this work in collaboration with Dr. Russell Taichman, Professor of Dentistry, Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry. "We are honored to have been granted this award," commented Dr. Denis Rodgerson, Senior Scientist at NeoStem. "It will enable us, together with Dr. Taichman as co-principal investigator, and his colleagues, Drs. Paul Kresbach and David Kohn, to explore the significant potential for the VSEL(TM) Technology as an autologous adult stem cell-based therapy for osteoporosis and other bone diseases."

Under the Recovery Act, the NIH has established a new program entitled Research and Research Infrastructure "Grand Opportunities," also known as the "GO" grants program. This new program is designed to support large-scale research projects that accelerate critical breakthroughs, early and applied research on cutting-edge technologies, and new approaches to improve the synergy and interactions among multi and interdisciplinary research teams. The program is intended for research activities that have high, short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development in new fields of investigation. "We are gratified to receive this funding from NIH," said Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer. "Our broad range of clinical research activities supports our novel approach to characterizing adult pluripotent stem cells taken from peripheral blood. We believe that our VESL technology will emerge as a competitive differentiator that will put us at the forefront of advances with autologous adult stem cell therapies in the field of regenerative medicine."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

The project described was supported by Award Number R43AR056893 from the National Institute Of Arthritis And Musculoskeletal And Skin Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Arthritis and Musculoskeletal And Skin Diseases or the National Institutes of Health.

            CONTACT:
            NeoStem, Inc.
            Robin Smith, Chief Executive Officer
            T: 212-584-4180
            E: rsmith@neostem.com

SOURCE NeoStem, Inc.


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
2. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
3. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
4. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
5. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
6. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
7. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
8. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
11. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):